Boehringer Ingelheim calls for 2018 Equine Research Awards proposalsAugust 6, 2018Boehringer Ingelheim is accepting proposals for the 2018 Advancement in Equine Research Awards for Equine Respiratory Disease Research. Veterinarians, diagnosticians, and public and private researchers in the U.S., Canada, and Mexico are eligible to submit proposals for research programs that help advance the diagnosis, treatment, and understanding of equine disease. Boehringer Ingelheim will present five separate $15,000 awards focused on two specific disease topics. Proposals must address either equine infectious respiratory disease or equine asthma syndrome for consideration. Proposals must be submitted by Sept. 15 and will be reviewed by an independent review board that will peer review and select proposals based on probability of successfully completing the project, potential for impact to the equine industry, originality, and scientific quality. The awards will be announced at the 64th annual American Association of Equine Practitioners Convention scheduled for Dec. 1-5. Those wishing to participate in the awards program must submit a proposal, a cover letter, a curriculum vitae, and two letters of recommendation by Sept. 15 to Boehringer Ingelheim Vetmedica Inc., Attn: Dr. Steve Grubbs, 2018 Advancement in Equine Research Awards, 3902 Gene Field Rd., St. Joseph, MO 64506. Launched in 2011, more than $455,000 has been awarded to date …
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
Heartgard producer announces heartworm awareness campaignApril 16, 2018 Merial, now a part of Boehringer Ingelheim (BI), announced a multifaceted campaign to assist veterinarians and clinic teams in promoting the consistent use of heartworm preventive medications for their patients. The announcement follows a recent survey conducted by the company, which showed a decreased use of year-round heartworm preventive measures and a corresponding increase in instances of the disease. "After years of steady progress in reducing the numbers of heartworm-positive cases in pets, a concerning backward slide has occurred over the past few years," said Stephen Jones, DVM, past president of the American Heartworm Society. "It is commendable that the Heartgard Plus team has recognized the urgency of the situation and is moving quickly and aggressively to address this challenge." Through the initiative, Merial's team will engage with both veterinarians and pet owners to listen to the challenges they face in starting and keeping their patients/pets on heartworm preventive medications for year-round protection. From this data, best practices for encouraging consistent usage will be determined and shared with the animal care community. The first component of the campaign, Take the Paw Pledge, launches this month, with veterinarians across the country asking their clients to commit …
Experts discuss lone star tick population, associated diseaseMarch 2, 2018Three health professionals in human allergy, parasitology, and entomology brought new perspectives on the lone star tick issue during a panel discussion sponsored by Boehringer Ingelheim at VMX: Veterinary Meeting & Expo 2018 in Orlando, Fla. Onyinye Iweala, MD, Ph.D., allergist and immunologist at the University of North Carolina-Chapel Hill; Brian Herrin, DVM, Ph.D., DACVM, assistant professor at Kansas State University College of Veterinary Medicine; and Thomas Mather, Ph.D., professor of entomology and director of the University of Rhode Island TickEncounter Resource Center, presented a review of the diseases transmitted by the Lone Star tick and its appearance in different parts of the U.S. "National news coverage has already underscored the presence of the lone star tick in areas of the U.S. and Canada," said Zach Mills, DVM, executive director, U.S. Pet Vet Veterinary Professional Services at Boehringer Ingelheim. "This panel offered a timely discussion for veterinarians on the wide range of diseases this parasite can transmit, including a red meat allergy in humans." Three perspectives on the lone star tick Dr. Herrin led off the session with an overview of the diseases that can be transmitted by the lone star tick emphasizing …
Boehringer Ingelheim, Merial launch Recombitek Oral BordetellaFebruary 14, 2018Merial, now part of Boehringer Ingelheim, has launched Recombitek Oral Bordetella, an oral vaccine shown to be effective against canine infectious tracheobronchitis caused by Bordetella bronchiseptica, the company reported. Clinical studies suggest that as a mucosal vaccine, it offers dogs a robust immune response after a single dose, according to the manufacturer. B. bronchiseptica, one of the primary pathogens responsible for canine infectious respiratory disease complex, is unique in its ability to evade the immune system for weeks to months. During this time, a dog that appears clinically normal could be exposing other dogs. "For many dogs, oral delivery may mean a less stressful experience without the unpleasant sneeze backs of alternative vaccines delivered through the nose," said Zach Mills, DVM, executive director of Boehringer Ingelheim's U.S. Pet Vet Veterinary Professional Services. "The packaging's flip-top vial cap allows for easy opening by veterinary staff, and the safe, needle-free pipette simplifies the vaccination process while reducing risk of injury." Recombitek Oral Bordetella is administered into the dog's buccal cavity. Recombitek vaccines are backed by the Pet Vaccines Customer Satisfaction Guarantee. Visit boehringer-ingelheim.com for more information.
Boehringer Ingelheim panel to discuss lone star ticks at Florida vet conferenceJanuary 31, 2018At 2018 VMX: Veterinary Meeting & Expo in Orlando, Fla., Boehringer Ingelheim will host a panel discussion on the diseases transmitted by the lone star tick affecting dogs and humans, "Lone Star Tick: Risk to Dogs, Risk to Humans." According to the Centers for Disease Control and Prevention, lone star ticks are found in at least 30 U.S. states, and are they are spreading to new areas of the country. The panel discussion will include five important facts about ticks that all veterinarians should know, tips for treatment of tick-borne illness in pets, and an update on a human allergy to red meat associated with the lone star tick. Panelists include Onyinye Iweala, MD, Ph.D., allergist, University of North Carolina-Chapel Hill whose research includes the alpha-gal meat allergy in humans; Brian Herrin, DVM, Ph.D., DACVM, assistant professor at Kansas State University College of Veterinary Medicine; and Thomas Mather, Ph.D., professor of entomology and director of the TickEncounter Resource Center at the University of Rhode Island. The discussion is scheduled to take place in the VMX Expo Hall Education Square on Tuesday, Feb. 6, at 9:55 - 10:55 a.m. and 10:55 - 11:55 a.m.
Boehringer Ingelheim announces $80M expansion investmentDecember 5, 2017Boehringer Ingelheim announced it will invest more than $80 million to expand its existing facilities in Athens, Ga., and St. Joseph, Mo., to accommodate increased production of animal vaccines. The company's facility in Athens, Ga., will grow from its current footprint of approximately 350,000 square feet to 400,000 square feet, and will nearly double its filling capacity for companion animal and avian vaccines. Construction is slated to begin in the fourth quarter of 2017 and will continue through 2019, with commercial production anticipated to begin in the second half of 2019. The facility employs approximately 400; research and development operations also are based there. The company expects to add 50 positions over the next three years to support the expansion. Construction at the company's facility in St. Joseph, Mo., also will begin in the fourth quarter 2017 on a 13,000-square-foot expansion to accommodate increased production of livestock animal vaccines sold in the U.S. and globally. The manufacturing operation is part of a 700,000-square-foot total campus in St. Joseph, which also includes a warehouse, research and development, and other support functions. Twenty additional jobs will be created over the next few years to support the increased …
Boehringer Ingelheim funds three equine research awardsNovember 22, 2017Boehringer Ingelheim has selected three research proposals to fund as part of its 2017 Advancement in Equine Research Award program. The company has given more than $470,000 to advancing the knowledge of equine infectious disease since 2011. "For the past six years, BI has supported equine research into identifying new disease treatment and prevention methods," said Steve Grubbs, DVM, Ph.D., DACVIM, equine technical manager at Boehringer Ingelheim. "Through this program we are committed to helping advance the understanding, diagnosis, and prevention of infectious equine diseases." The 2017 Equine Research Award recipients are: Nicola Pusterla, DVM, Ph.D., DACVIM, and Sharon Spier, DVM, PhD., DACVIM, University of California, Davis School of Veterinary Medicine. "Investigation of the role of non-steroidal anti-inflammatory and anti-histaminic drugs on the humoral response to a commercial Corynebacterium pseudotuberculosis vaccine given to naïve healthy horses." Nicola Pusterla, DVM, Ph.D., DACVIM, UC Davis School of Veterinary Medicine. "Investigation of the Florida sublineage clade affiliation of equine influenza virus strains using novel multiplex real-time quantitative PCR in nasal secretions submitted to a diagnostic laboratory (2012-2017)." Rebecca P. Wilkes, DVM, Ph.D., DACVM, University of Georgia College of Veterinary Medicine. "Targeted next-generation sequencing panel for detection of equine pathogens." …
Boehringer Ingelheim unveils new equine brand platformAugust 31, 2017Boehringer Ingelheim is introducing a new brand platform: Unbridle Your Potential—health care products to help unlock the potential in each horse.
Researchers step up fight against parasitesMay 20, 2016Pharmaceutical giant Boehringer Ingelheim Animal Health is teaming up with a Scottish university and another European institution to find better treatments for parasitic diseases.
